<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220509054789N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-23</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effectiveness of mouthwashes containing betamethasone and dexamethasone in improving oral lichen planus</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of mouthwashs containing betamethasone with dexamethasone in the improvement of oral lichen planus lesions: A randomized double blind placebo controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64602</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly divided into two groups A and B. Sealed envelopes will be used for this purpose. They will be sealed by writing group A or B inside the envelopes. The envelopes are then mixed and the first envelope is removed at each patient's visit and assigned to the group inside the envelope. The examining dentist does not know which group A and B each belong to, Blinding description: he double-blind method will be implemented, In this way, the patient, researcher and data analyzer will not be aware of the contents of the bottles. Sampling and assignment of individuals to each group will remain secret for the patient and the researcher until the end of the study. Bottles with similar appearance will be divided into two categories.</study_design>
      <phase>3</phase>
      <hc_freetext>Lichen planus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 15 cc long-acting betamethasone (Kimia Drug Co.) in combination with 200 cc of AlMg stomach syrup, 3 times a day, 5 cc each time for 30 seconds, for 6 weeks. Patients will be instructed to gargle 5 cc each time for 30 seconds with betamethasone mouthwash inside their mouths, and to avoid eating and drinking for half an hour. In order to know about consumption or forgetting, the patients are asked to keep a diary and tick the consumption or non-consumption and hand it over to the researcher. This treatment will last up to 6 weeks. Then, after 6 weeks, the diameter of the lesions will be measured again. Intervention 2: Control group: 15 cc long-acting Dexamethasone (Kimia Drug Co.) in combination with 200 cc of AlMg stomach syrup, 3 times a day, 5 cc each time for 30 seconds, for 6 weeks. Patients will be instructed to gargle 5 cc each time for 30 seconds with dexamethasone mouthwash inside their mouths, and to avoid eating and drinking for half an hour. In order to know about consumption or forgetting, the patients are asked to keep a diary and tick the consumption or non-consumption and hand it over to the researcher. This treatment will last up to 6 weeks . Then, after 6 weeks, the diameter of the lesions will be measured again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Khademnezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ّFaculty of dentistry, Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3333 6097</telephone>
        <email>khademnezhad@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sahar Khademnezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ّFaculty of dentistry, Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3333 6097</telephone>
        <email>khademnezhad@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with OLP who have not received treatment so far.
Confirmation of OLP diagnosis by histological sampling
Age above 18 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Having uncontrolled diabetes
Stomach ulcer
Having high blood pressure
Suffering from a systemic disease for which corticosteroid administration is contraindicated
Age below 18 years
Observation of dysplasia in histopathological view
Get other treatments for OLP</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lichen planus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 15 cc long-acting betamethasone (Kimia Drug Co.) in combination with 200 cc of AlMg stomach syrup, 3 times a day, 5 cc each time for 30 seconds, for 6 weeks. Patients will be instructed to gargle 5 cc each time for 30 seconds with betamethasone mouthwash inside their mouths, and to avoid eating and drinking for half an hour. In order to know about consumption or forgetting, the patients are asked to keep a diary and tick the consumption or non-consumption and hand it over to the researcher. This treatment will last up to 6 weeks. Then, after 6 weeks, the diameter of the lesions will be measured again.</i_keyword>
      <i_keyword>Control group: 15 cc long-acting Dexamethasone (Kimia Drug Co.) in combination with 200 cc of AlMg stomach syrup, 3 times a day, 5 cc each time for 30 seconds, for 6 weeks. Patients will be instructed to gargle 5 cc each time for 30 seconds with dexamethasone mouthwash inside their mouths, and to avoid eating and drinking for half an hour. In order to know about consumption or forgetting, the patients are asked to keep a diary and tick the consumption or non-consumption and hand it over to the researcher. This treatment will last up to 6 weeks . Then, after 6 weeks, the diameter of the lesions will be measured again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lesions size. Timepoint: Before and 6 weeks after the intervention. Method of measurement: Using the Thongprasom scoring system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-27</approval_date>
        <contact_name>Research ethics comittees of Tabriz university of medical sciences</contact_name>
        <contact_address>Research Vice- Chancellor, Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz, Iran, , Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
